

Amendments to the Claims

This listing of claims will replace all prior listings of claims in the application.

1-17. (Cancelled)

18. (Currently amended): An antibody which specifically ~~reacts with~~ binds to an epitope in a human IL-11 Receptor (IL-11R) protein, wherein said IL-11R protein comprises an amino acid sequence from SEQ ID NO:2 selected from the group consisting of amino acids 26 to 111, amino acids 112 to 365, amino acids 366 to 390, and amino acids 391 to 422.

19-38. (Cancelled)

39. (Previously presented): The antibody of claim 18, wherein said antibody is a neutralizing antibody.

40. (Previously presented): The antibody of claim 18, wherein said antibody blocks binding of IL-11 to a human IL-11 receptor.

41. (Previously presented): The antibody of claim 18, wherein said antibody is a polyclonal antibody.

42. (Previously presented): The antibody of claim 18, wherein said antibody is a monoclonal antibody.

43. (Currently amended): The antibody of claim 18, wherein said antibody specifically reacts with binds to a protein comprising the amino acid sequence of SEQ ID NO:2.

44. (Currently amended): The antibody of claim 18, wherein said antibody specifically reacts with binds to a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 26 to 422.

45. (Currently amended): The antibody of claim 18, wherein said antibody specifically reacts with binds to a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 26 to 365.

46. (Currently amended): The antibody of claim 18, wherein said antibody specifically reacts with binds to a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 391 to 422.

47. (Currently amended): The antibody of claim 18, wherein said antibody specifically reacts with binds to a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 112 to 422.

48. (Currently amended): The antibody of claim 18, wherein said antibody specifically
~~reacts with binds to~~ a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 112 to 365.

49. (Currently amended): The antibody of claim 18, wherein said antibody specifically
~~reacts with binds to~~ a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 26 to 359.

50. (Currently amended): The antibody of claim 18, wherein said antibody specifically
~~reacts with binds to~~ a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 26 to 345.

51. (Currently amended): The antibody of claim 18, wherein said antibody specifically
~~reacts with binds to~~ a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 26 to 324.

52. (Previously presented): The antibody of claim 62, wherein said antibody is obtained using as an immunogen a protein with a cysteine residue at the carboxyl terminus, wherein said protein comprises an amino acid sequence from SEQ ID NO:2 selected from the group consisting of amino acids 26 to 111, amino acids 112 to 365, amino acids 366 to 390, and amino acids 391 to 422.

53. (Previously presented): The antibody of claim 62, wherein said antibody is obtained using as an immunogen a protein with tyrosine residues replaced with sulfated tyrosine residues.

54. (Cancelled)

55. (Previously presented): The antibody of claim 62, wherein said immunogen is conjugated to a hapten.

56. (Previously presented): The antibody of claim 55, wherein said hapten is keyhole limpet hemocyanin (KLH).

57. (Previously presented): A pharmaceutical composition comprising the antibody of claim 18 and a pharmaceutically acceptable carrier.

58. (Currently amended): A neutralizing antibody that binds specifically to an epitope in a human IL-11 Receptor (IL-11R) protein, wherein said IL-11R protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2 from amino acids 26 to 111, SEQ ID NO:2 from amino acids 112 to 365, SEQ ID NO:2 from 366 to 390, and SEQ ID NO:2 from 391 to 422, wherein said neutralizing antibody blocks binding of IL-11 to a human IL-11 receptor.

59. (Currently amended): A pharmaceutical composition comprising the composition antibody of claim 58 and a pharmaceutically acceptable carrier.

60. (Currently amended): The antibody of claim 18, wherein said antibody specifically ~~reacts with~~ binds to a protein comprising an amino acid sequence of SEQ ID NO:2 from 26 to 111.

61. (Currently amended): The antibody of claim 18, wherein said antibody specifically ~~reacts with~~ binds to a protein comprising an amino acid sequence of SEQ ID NO:2 from 366 to 390.

62. (Previously presented): An antibody obtained using as an immunogen an IL-11 Receptor (“IL-11R”) protein, wherein said IL-R protein comprises an amino acid sequence from SEQ ID NO:2 selected from the group consisting of amino acids 26 to 111, amino acids 112 to 365, amino acids 366 to 390, and amino acids 391 to 422.

63. (Previously presented): The antibody of claim 18, wherein said antibody is an isolated antibody.

64. (Previously presented): The antibody of claim 58, wherein said antibody is an isolated antibody.

65. (Previously presented): The antibody of claim 62, wherein said antibody is an isolated antibody.